Sarepta Therapeutics Inc. is investing up to $105 million in the latest gene therapy spinoff from Nationwide Children’s Hospital – and signed an option to acquire the company for an undisclosed but higher amount if clinical trial results are promising.
Myonexus Therapeutics Inc. gets $60 million upfront to start patient trials, which are conducted at the Columbus pediatric hospital. The remaining $45 million will be paid out over two years if the company reaches performance milestones during the trials. Sarepta may exercise its option to acquire the company after that.
Click here to read the complete article. Story excerpt provided by Columbus Business First. Written by Carrie Ghose. Originally published May 8, 2018.